CLINICAL DATA MANAGEMENT FEATURED ARTICLES
CLINICAL DATA MANAGEMENT WHITE PAPER & ARTICLES
-
The FDA’s 2026 guidance has put an end to "wellness by disclaimer." Learn how new standards for wearables and apps impact study design, participant safety, and the evolving ethical role of the IRB.
-
Modernize clinical trials by replacing slow international wires with local digital payments. Reduce participant friction and ensure fair, instant reimbursements across the globe.
-
Emerging trends in HEOR reveal how AI, real‑world evidence, value‑based care, digital health, and evolving affordability pressures are reshaping global healthcare.
-
AI acceleration and digital fragmentation are reshaping clinical trials. Discover five imperatives driving interoperability, smarter site enablement, and data‑ready workflows for future‑ready operations.
-
Don’t let legacy vendor inertia jeopardize your trial. Discover why agility and deep RTSM expertise are the new benchmarks for reducing risk and ensuring precision in clinical operations.
CLINICAL DATA MANAGEMENT APPLICATIONS & STUDIES
-
How A Complex Personalized Medicine Trial Migrated RTSM Software Without Disruption3/26/2026
Discover how a clinical-stage biotech automated its supply chain to protect patient enrollment and eliminate manual errors in a complex, multi-national genetic medicine trial.
-
How A Rare Disease Biotech Replaced Manual Processes With RTSM Software3/26/2026
Discover how a clinical-stage biotech automated its supply chain to protect patient enrollment and eliminate manual errors in a complex, multi-national genetic medicine trial.
-
Outgrowing Excel: Implementing RTSM Software In A Live Phase I Trial3/26/2026
Moving from manual spreadsheets to RTSM mid-study requires precision. Learn how clinical teams maintain trial momentum while executing protocol changes without delays.
-
Advancing Neuromuscular Research with Digital Endpoints1/20/2026
Explore cutting-edge digital measures that capture peak mobility and activity in real-world settings, offering meaningful insights into disease progression in neuromuscular disorders.
-
Expanding Clinical Research In East Africa With Digital Innovation12/11/2025
Africa carries 25% of the world’s disease burden but hosts only 1% of clinical trials. Discover technology-driven strategies that close this gap and transform research access in underserved regions.
SOLUTIONS
- Delivering The Digital Future
- Why Customers Are Switching To Medidata CTMS And eTMF
- Sikich SuiteSuccess For Life Sciences Built On Netsuite
- Powering Smarter Treatments And Healthier People
- Greenphire Patient Payments
- Wearable Device Comparison Guide: Medical-Grade Or Consumer Device?
- Managing Risk In Clinical Trials
- Comprehensive Global Medical Information Services
- Suvoda Scheduling
- Q: What Does 'Powered by Block Clinical' Mean?
NEWS
-
Dielectric Partners With Foccus Digital For Brazilian Broadcast Growth8/15/2025
Dielectric’s Brazilian presence is about to radiate stronger through a new partnership with Foccus Digital that expand Dielectric’s broadcast business throughout the country.
-
How Lakes Connect To Groundwater Critical For Resilience To Climate Change7/9/2025
The study drew on data from 350 lakes across 18 European countries, collected between 2022 and 2024, to provide a comprehensive picture of how the continent’s lakes are coping with climate change.
-
Puraffinity Signs First Commercial Agreement For Full-Scale Deployment Of Its PFAS Removal Technology6/2/2025
The agreement was signed with Envytech Solutions, the leading expert in mobile water treatment in the Nordic region and a member of the Sortera Group, which operates across the Nordics and the UK.
-
The Persistence Of PFAS - IDTechEx Covers Growing PFAS Regulations4/24/2025
Per- and polyfluoroalkyl substances (PFAS) are a broad group of chemicals that includes both polymers and non-polymers used in many applications, from transport to consumer products.
-
Quantum Biopharma Announces Signing Of An Agreement With A Global Pharmaceutical Contract Research Organization To Prepare An IND (Investigational New Drug) Application Package For Lucid-21-302 (Lucid-MS), A First-In-Class Treatment For Multiple Sclerosis5/20/2025
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the US FDA.